NYSE
BSX

Boston Scientific Corp

Medical Devices
Healthcare

Prices are adjusted according to historical splits.

Boston Scientific Corp Stock Price

Vitals

Today's Low:
$53.35
Today's High:
$54.57
Open Price:
$54.47
52W Low:
$34.98
52W High:
$54.17
Prev. Close:
$54.56
Volume:
5635354

Company Statistics

Market Cap.:
$73.90 billion
Book Value:
12.417
Revenue TTM:
$13.05 billion
Operating Margin TTM:
16.36%
Gross Profit TTM:
$8.68 billion
Profit Margin:
6.92%
Return on Assets TTM:
4.09%
Return on Equity TTM:
5.18%

Company Profile

Boston Scientific Corp had its IPO on 1992-05-18 under the ticker symbol BSX.

The company operates in the Healthcare sector and Medical Devices industry. Boston Scientific Corp has a staff strength of 45,000 employees.

Stock update

Shares of Boston Scientific Corp opened at $54.47 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $53.35 - $54.57, and closed at $53.42.

This is a -2.09% slip from the previous day's closing price.

A total volume of 5,635,354 shares were traded at the close of the day’s session.

In the last one week, shares of Boston Scientific Corp have slipped by -0.37%.

Boston Scientific Corp's Key Ratios

Boston Scientific Corp has a market cap of $73.90 billion, indicating a price to book ratio of 3.8306 and a price to sales ratio of 5.2793.

In the last 12-months Boston Scientific Corp’s revenue was $13.05 billion with a gross profit of $8.68 billion and an EBITDA of $3.28 billion. The EBITDA ratio measures Boston Scientific Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Boston Scientific Corp’s operating margin was 16.36% while its return on assets stood at 4.09% with a return of equity of 5.18%.

In Q1, Boston Scientific Corp’s quarterly earnings growth was a positive 210.8% while revenue growth was a positive 12%.

Boston Scientific Corp’s PE and PEG Ratio

Forward PE
24.2718
Trailing PE
85.6667
PEG
2.5307

Its diluted EPS in the last 12-months stands at $0.6 per share while it has a forward price to earnings multiple of 24.2718 and a PEG multiple of 2.5307. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Boston Scientific Corp’s profitability.

Boston Scientific Corp stock is trading at a EV to sales ratio of 6.0613 and a EV to EBITDA ratio of 30.6036. Its price to sales ratio in the trailing 12-months stood at 5.2793.

Boston Scientific Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$32.89 billion
Total Liabilities
$4.08 billion
Operating Cash Flow
$-484000000.00
Capital Expenditure
$111 million
Dividend Payout Ratio
0%

Boston Scientific Corp ended 2024 with $32.89 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $32.89 billion while shareholder equity stood at $17.85 billion.

Boston Scientific Corp ended 2024 with $210.00 million in deferred long-term liabilities, $4.08 billion in other current liabilities, 17000000.00 in common stock, $-450000000.00 in retained earnings and $13.27 billion in goodwill. Its cash balance stood at $570.00 million and cash and short-term investments were $570.00 million. The company’s total short-term debt was $510,000,000 while long-term debt stood at $0.

Boston Scientific Corp’s total current assets stands at $5.70 billion while long-term investments were $0 and short-term investments were $4.00 million. Its net receivables were $2.08 billion compared to accounts payable of $868.00 million and inventory worth $2.05 billion.

In 2024, Boston Scientific Corp's operating cash flow was $-484000000.00 while its capital expenditure stood at $111 million.

Comparatively, Boston Scientific Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$53.42
52-Week High
$54.17
52-Week Low
$34.98
Analyst Target Price
$58.22

Boston Scientific Corp stock is currently trading at $53.42 per share. It touched a 52-week high of $54.17 and a 52-week low of $54.17. Analysts tracking the stock have a 12-month average target price of $58.22.

Its 50-day moving average was $52.25 and 200-day moving average was $49.82 The short ratio stood at 1.46 indicating a short percent outstanding of 0%.

Around 26.7% of the company’s stock are held by insiders while 9396.4% are held by institutions.

Frequently Asked Questions About Boston Scientific Corp

The stock symbol (also called stock or share ticker) of Boston Scientific Corp is BSX

The IPO of Boston Scientific Corp took place on 1992-05-18

Similar Industry Stocks (Medical Devices)

Last Price
Chg
Chg%
$34.42
0.16
+0.47%
$4.48
0.07
+1.59%
NUTECH GLOBAL LTD. (NUTECGLOB)
$37.05
-1.95
-5%
$10.4
-0.5
-4.59%
$618.2
-2.55
-0.41%
$40.56
-0.02
-0.05%
$1.74
0
0%
$355.35
-32.25
-8.32%
COAL INDIA LTD. (COALINDIA)
$270.75
-8.2
-2.94%
$4.76
0.08
+1.71%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Address

300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234